Vanda Pharmaceuticals (NASDAQ:VNDA) Raised to Hold at Zacks Research

Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Wednesday, Zacks reports.

Other equities analysts have also recently issued reports about the stock. B. Riley Financial reaffirmed a “buy” rating and set a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Wall Street Zen raised shares of Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 31st. HC Wainwright reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, October 15th. Finally, Oppenheimer began coverage on Vanda Pharmaceuticals in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $13.50.

Vanda Pharmaceuticals Stock Down 7.5%

Shares of VNDA opened at $3.59 on Wednesday. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average of $4.66 and a 200 day moving average of $6.14. The company has a market cap of $217.09 million, a PE ratio of -0.78 and a beta of 0.74. Vanda Pharmaceuticals has a 52-week low of $3.57 and a 52-week high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.31. Vanda Pharmaceuticals had a negative net margin of 119.87% and a negative return on equity of 62.70%. The business had revenue of $69.81 million for the quarter, compared to analysts’ expectations of $69.20 million. On average, sell-side analysts expect that Vanda Pharmaceuticals will post -2.53 EPS for the current year.

Institutional Trading of Vanda Pharmaceuticals

A number of large investors have recently made changes to their positions in VNDA. Quantbot Technologies LP bought a new position in shares of Vanda Pharmaceuticals in the second quarter worth about $29,000. Legal & General Group Plc bought a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at about $34,000. Allworth Financial LP bought a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at about $43,000. Walleye Capital LLC purchased a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at about $76,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at about $93,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals News Summary

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Director Charles Cliff Duncan bought a combined 10,000 shares from November 3–5 for approximately $38,069, increasing his ownership. SEC ownership filing
• Neutral Sentiment: HC Wainwright maintained its Buy rating and raised its 2026 EPS estimate to a loss of $2.45 from a loss of $3.03, including a narrower projected Q4 loss.
• Negative Sentiment: HC Wainwright lowered estimates for Q2–Q4 2027 and cut its full-year 2027 EPS forecast to a loss of $1.02 from a loss of $0.94, signaling a less favorable outlook for those periods.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.